Ranking Alexa Global: # 16,270,078
Server:Apache...
The main IP address: 199.34.228.70,Your server United States,San Francisco ISP:Weebly Inc. TLD:uk CountryCode:US
The description :guidance on the use of drugs to treat tuberculosis and multi-drug resistant tuberculosis...
This report updates in 07-Jul-2018
Created Date: | 11-Jan-2014 |
Changed Date: | 11-Jan-2014 |
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host tbdrugmonographs.co.uk. Currently, hosted in United States and its service provider is Weebly Inc. .
Latitude: | 37.775699615479 |
Longitude: | -122.39520263672 |
Country: | United States (US) |
City: | San Francisco |
Region: | California |
ISP: | Weebly Inc. |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.
Content-Length: | 8226 |
X-Host: | pages16.sf2p.intern.weebly.net |
Content-Encoding: | gzip |
Set-Cookie: | is_mobile=0; path=/; domain=www.tbdrugmonographs.co.uk, language=en; expires=Sat, 21-Jul-2018 08:56:54 GMT; Max-Age=1209600; path=/, gdpr-kb=1; expires=Tue, 04-Jul-2028 08:56:54 GMT; Max-Age=315360000; path=/ |
Vary: | X-W-SSL,Accept-Encoding,User-Agent |
Keep-Alive: | timeout=10, max=66 |
Server: | Apache |
Connection: | Keep-Alive |
ETag: | W/"75b17a670c71cfe0d1f161cf9b50884a-gzip" |
X-UA-Compatible: | IE=edge,chrome=1 |
Cache-Control: | private |
Date: | Sat, 07 Jul 2018 08:56:54 GMT |
Content-Type: | text/html; charset=UTF-8 |
soa: | ns05.domaincontrol.com. dns.jomax.net. 2016081700 28800 7200 604800 600 |
ns: | ns06.domaincontrol.com. ns05.domaincontrol.com. |
ipv4: | IP:199.34.228.70 ASN:27647 OWNER:WEEBLY - Weebly, Inc., US Country:US |
mx: | MX preference = 10, mail exchanger = mailstore1.secureserver.net. MX preference = 0, mail exchanger = smtp.secureserver.net. |
tb drug monographs home baseline & ongoing monitoring tests drug monographs amikacin bedaquiline capreomycin clarithromycin clofazimine co-amoxiclav cycloserine delamanid ethambutol imipenem/cilastatin isoniazid levofloxacin linezolid meropenem moxifloxacin ofloxacin p-aminosalicylic acid prothionamide pyrazinamide rifabutin rifampicin rifapentine streptomycin thioacetazone for patients updates publications references about us contact a uk based resource to support the monitoring and safe use of anti-tuberculosis drugs and second line treatment of multidrug-resistant tuberculosis. introduction this guideline is to aid monitoring for adverse effects during the treatment of mdr-tb. it is not a treatment guide or a guide for monitoring the progress of treatment. advice is based on best available evidence and when this is poor, expert consensus. the monitoring guidelines were developed in the context of the uk where treatment within the nhs is standard and there the tests advised are readily available. for treatment guidance please refer to the who treatment guideline and the bts mdr-tb clinical advisory service. treatment of mdr-tb should always be undertaken in consultation with local experts as well as published guidance. due to the complexity of treatment regimens and comorbidity associated with the disease itself, more frequent monitoring may be needed in individual patients and this should be guided by the clinician in charge of the patient’s care. our recommendations are predominantly based on consensus opinion from tb physicians, pharmacists, nursing staff and specialties including audiology and ophthalmology and drug advisory organisations including the fda and bnf. we also appreciate that most patients with mdr-tb are established on treatment whilst an in-patient and may require more frequent blood test monitoring during the initial phase of treatment. we have produced this document to provide advice on the frequency of monitoring which should occur, at minimum , in all patients on mdr-tb treatment. many side effects cannot easily be measured with routine testing. as such, it is important that all healthcare staff routinely assess patients for symptoms with reference to the potential adverse reactions listed for each drug. all recommendations below should cover any combination of drugs. where additional monitoring is required with a specific drug we have noted this and provided a source for further information in the form of individual drug monographs. therapeutic drug level monitoring advice is available in individual drug monographs. patient information leaflet mdr_leaflet_2015_updated_a4.pdf file size: 1075 kb file type: pdf download file full guidance: pdf last updated june 2018 mdrtb_adr_monitoring_guidancejune_2018.pdf file size: 2427 kb file type: pdf download file useful links a british thoracic society mdr-tb clinical advisory service (select mdrtb service at the bottom of the page) who guidance on the treatment of mdr-tb who fact sheet on mdr-tb short course \who mdr-tb short course faqs bts clinical statement mdr-tb short course tb alert patient information materials the truth about tb community resources tb frequently asked questions - british thoracic society treatment of tb/ hiv co-infection guidelines from bhiva hiv drug interactions hepatitis drug interactions ​resist-tb useful resources feedback [email protected] the information we have provided here is not exhaustive and is aimed as a practical tool for aid in the management of patients with mdr-tb. a list of references is included in a separate document however the majority of these recommendations are based on expert consensus. feedback is welcomed. this is a drug monitoring guideline, for treatment guidance please refer to the who treatment guideline http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf and the bts mdr-tb clinical advisory service http://www.brit-thoracic.org.uk/delivery-of-respiratory-care/tuberculosis/mdrtb-clinical-advice-service.aspx.
http://www.tbdrugmonographs.co.uk/updates.html
http://www.tbdrugmonographs.co.uk/capreomycin.html
http://www.tbdrugmonographs.co.uk/cycloserine.html
http://www.tbdrugmonographs.co.uk/streptomycin.html
http://www.tbdrugmonographs.co.uk/uploads/2/8/9/4/28941471/mdrtb_adr_monitoring_guidancejune_2018.pdf
http://www.tbdrugmonographs.co.uk/amikacin.html
http://www.tbdrugmonographs.co.uk/imipenemcilastatin.html
http://www.tbdrugmonographs.co.uk/prothionamide.html
http://www.tbdrugmonographs.co.uk/thioacetazone.html
http://www.tbdrugmonographs.co.uk/co-amoxiclav.html
http://www.tbdrugmonographs.co.uk/clarithromycin.html
http://www.tbdrugmonographs.co.uk/pyrazinamide.html
http://www.tbdrugmonographs.co.uk/isoniazid.html
http://www.tbdrugmonographs.co.uk/uploads/2/8/9/4/28941471/mdr_leaflet_2015_updated_a4.pdf
http://www.tbdrugmonographs.co.uk/delamanid.html
brit-thoracic.org.uk
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Domain name:
tbdrugmonographs.co.uk
Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 11-Jan-2014
Registrar:
GoDaddy.com, LLP. [Tag = GODADDY]
URL: http://uk.godaddy.com
Relevant dates:
Registered on: 11-Jan-2014
Expiry date: 11-Jan-2019
Last updated: 11-Jan-2014
Registration status:
Registered until expiry date.
Name servers:
ns05.domaincontrol.com
ns06.domaincontrol.com
WHOIS lookup made at 09:57:02 07-Jul-2018
--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REFERRER http://www.nominet.org.uk
REGISTRAR Nominet UK
SERVERS
SERVER co.uk.whois-servers.net
ARGS tbdrugmonographs.co.uk
PORT 43
TYPE domain
DOMAIN
SPONSOR
GoDaddy.com, LLP. [Tag = GODADDY]
URL: http://uk.godaddy.com
Relevant dates:
CREATED 11-Jan-2014
CHANGED 11-Jan-2014
STATUS
Registered until expiry date.
NSERVER
NS05.DOMAINCONTROL.COM 216.69.185.3
NS06.DOMAINCONTROL.COM 173.201.70.3
NAME tbdrugmonographs.co.uk
DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.
REGISTERED no
The following list shows you to spelling mistakes possible of the internet users for the website searched .